A major Australian study has found that metastatic breast cancer patients who took the drug paclitaxel (Taxol) had a higher survival rate, with a better quality of life, than patients who did not take the drug. The study, conducted by researchers at the Sydney Cancer Centre of the University of Sydney and published in the August issue of the Journal of Clinical Oncology, compared patients who took Taxol with those who took a combination of standard chemotherapy drugs. The Taxol patients had a 39 percent two-year survival rate, while the combination chemotherapy patients had a 20 percent survival rate.
Return to the Perry Hookman, M.D., P.A. Home Page